nach oben

Medical Oncology

Erschienen in:

01.06.2024 | Review Article

The role of IGFBP-3 in tumor development and progression: enlightenment for diagnosis and treatment

verfasst von: Yudi Wang, He Zhang, Xuehua Zhang, Peizheng Mu, Leilei Zhao, Ruomei Qi, Yurui Zhang, Xiao Zhu, Yucui Dong

Erschienen in: Medical Oncology | Ausgabe 6/2024

Einloggen, um Zugang zu erhalten

Abstract

IGFBP-3 is aberrantly expressed in many tumor types, and its serum and tumor tissue levels provide auxiliary information for assessing the degree of tumor malignancy and patient prognosis, making it a potential therapeutic target for human malignancies and conferring it remarkable clinical value for determining patient prognosis. In this review, we provide a comprehensive overview of the aberrant expression, diverse biological effects, and clinical implications of IGFBP-3 in tumors and its role as a potential prognostic marker and therapeutic target for tumors. In addition, we summarize the signaling pathways through which IGFBP-3 exerts its effects. IGFBP-3 comprises an N-terminal, an intermediate region, and a C-terminal structural domain, each exerting different biological effects in several tumor cell types in an IGF-dependent/non-independent manner. IGFBP-3 shares an intricate relationship with the tumor microenvironment, thereby affecting tumor growth. Overall, IGFBP-3 is an essential regulatory factor that mediates tumor occurrence and progression. Gaining deeper insights into the fundamental characteristics of IGFBP-3 and its role in various tumor types will provide new perspectives and allow for the development of novel strategies for cancer diagnosis, treatment, and prognostic evaluation.

LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett. 2003;195:127–37.PubMedCrossRef

Rajaram SBD, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev. 1997;18:801–31.PubMed

Ding H, Wu T. Insulin-like growth factor binding proteins in autoimmune diseases. Front Endocrinol (Lausanne). 2018;9:499.PubMedCrossRef

Abdolhoseinpour H, Mehrabi F, Shahraki K, Khoshnood RJ, Masoumi B, Yahaghi E, Goudarzi PK. Investigation of serum levels and tissue expression of two genes IGFBP-2 and IGFBP-3 act as potential biomarker for predicting the progression and survival in patients with glioblastoma multiforme. J Neurol Sci. 2016;366:202–6.PubMedCrossRef

Rosenfeld RG, Hwa V, Wilson E, Plymate SR, Oh Y. The insulin-like growth factor-binding protein superfamily. Growth Horm IGF Res. 2000;10(Suppl A):S16-17.PubMedCrossRef

Bhattacharyya N, Pechhold K, Shahjee H, Zappala G, Elbi C, Raaka B, Wiench M, Hong J, Rechler MM. Nonsecreted insulin-like growth factor binding protein-3 (IGFBP-3) can induce apoptosis in human prostate cancer cells by IGF-independent mechanisms without being concentrated in the nucleus. J Biol Chem. 2006;281:24588–601.PubMedCrossRef

Fujimoto M, Khoury JC, Khoury PR, Kalra B, Kumar A, Sluss P, Oxvig C, Hwa V, Dauber A. Anthropometric and biochemical correlates of PAPP-A2, free IGF-I, and IGFBP-3 in childhood. Eur J Endocrinol. 2020;182:363–74.PubMedPubMedCentralCrossRef

Dang YM, Huang G, Chen YR, Dang ZF, Chen C, Liu FL, Guo YF, Xie XD. Sulforaphane inhibits the proliferation of the BIU87 bladder cancer cell line via IGFBP-3 elevation. Asian Pac J Cancer Prev. 2014;15:1517–20.PubMedCrossRef

Zhou N, Sun Z, Li N, Ge Y, Zhou J, Han Q, Zhao L, Bai C. miR-197 promotes the invasion and migration of colorectal cancer by targeting insulin-like growth factor-binding protein 3. Oncol Rep. 2018;40:2710–21.PubMed

10.

Oh SH, Lee OH, Schroeder CP, Oh YW, Ke S, Cha HJ, Park RW, Onn A, Herbst RS, Li C, Lee HY. Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition. Mol Cancer Ther. 2006;5:2685–95.PubMedCrossRef

11.

Yu HRT. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000;92:1472–89.PubMedCrossRef

12.

Marimuthu A, Chavan S, Sathe G, Sahasrabuddhe NA, Srikanth SM, Renuse S, Ahmad S, Radhakrishnan A, Barbhuiya MA, Kumar RV, Harsha HC, Sidransky D, Califano J, Pandey A, Chatterjee A. Identification of head and neck squamous cell carcinoma biomarker candidates through proteomic analysis of cancer cell secretome. Biochim Biophys Acta. 2013;1834:2308–16.PubMedCrossRef

13.

Zhang X, Wang G, Gong Y, Zhao L, Song P, Zhang H, Zhang Y, Ju H, Wang X, Wang B, Ren H, Zhu X, Dong Y. IGFBP3 induced by the TGF-beta/EGFRvIII transactivation contributes to the malignant phenotype of glioblastoma. iScience. 2023;26:106639.PubMedPubMedCentralCrossRef

14.

Yang L, Li J, Fu S, Ren P, Tang J, Wang N, Shi X, Wu J, Lin S. Up-regulation of insulin-like growth factor binding protein-3 Is associated with brain metastasis in lung adenocarcinoma. Mol Cells. 2019;42:321–32.PubMedPubMedCentral

15.

Jogie-Brahim S, Feldman D, Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev. 2009;30:417–37.PubMedPubMedCentralCrossRef

16.

Yamada PM, Lee KW. Perspectives in mammalian IGFBP-3 biology: local vs. systemic action. Am J Physiol Cell Physiol. 2009;296:C954-976.PubMedCrossRef

17.

Baxter RC. IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer. 2014;14:329–41.PubMedCrossRef

18.

Johnson MA, Firth SM. IGFBP-3: a cell fate pivot in cancer and disease. Growth Horm IGF Res. 2014;24:164–73.PubMedCrossRef

19.

Yan X, Forbes BE, McNeil KA, Baxter RC, Firth SM. Role of N- and C-terminal residues of insulin-like growth factor (IGF)-binding protein-3 in regulating IGF complex formation and receptor activation. J Biol Chem. 2004;279:53232–40.PubMedCrossRef

20.

Buckway CKWE, Ahlsén M, Bang P, Oh Y, Rosenfeld RG. Mutation of three critical amino acids of the N-terminal domain of IGF-binding protein-3 essential for high affinity IGF binding. J Clin Endocrinol Metab. 2001;86:4943–50.PubMedCrossRef

21.

Hwa VOY, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev. 1999;20:761–87.PubMed

22.

Varma Shrivastav S, Bhardwaj A, Pathak KA, Shrivastav A. Insulin-like growth factor binding protein-3 (IGFBP-3): unraveling the role in mediating IGF-independent effects within the cell. Front Cell Dev Biol. 2020;8:286. PubMedPubMedCentralCrossRef

23.

Schedlich LJ, Graham LD. Role of insulin-like growth factor binding protein-3 in breast cancer cell growth. Microsc Res Tech. 2002;59:12–22.PubMedCrossRef

24.

Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23:824–54.PubMedCrossRef

25.

Schedlich LJ, Nilsen T, John AP, Jans DA, Baxter RC. Phosphorylation of insulin-like growth factor binding protein-3 by deoxyribonucleic acid-dependent protein kinase reduces ligand binding and enhances nuclear accumulation. Endocrinology. 2003;144:1984–93.PubMedCrossRef

26.

Cobb LJ, Liu B, Lee KW, Cohen P. Phosphorylation by DNA-dependent protein kinase is critical for apoptosis induction by insulin-like growth factor binding protein-3. Cancer Res. 2006;66:10878–84.PubMedCrossRef

27.

Fowlkes JLTK, Serra DM, Suzuki K, Nagase H. Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. Prog Growth Factor Res. 1995;6:255–63.PubMedCrossRef

28.

Ingermann AR, Yang YF, Han J, Mikami A, Garza AE, Mohanraj L, Fan L, Idowu M, Ware JL, Kim HS, Lee DY, Oh Y. Identification of a novel cell death receptor mediating IGFBP-3-induced anti-tumor effects in breast and prostate cancer. J Biol Chem. 2010;285:30233–46.PubMedPubMedCentralCrossRef

29.

Devi GRYD, Rosenfeld RG, Oh Y. Differential effects of insulin-like growth factor (IGF)-binding protein-3 and its proteolytic fragments on ligand binding, cell surface association, and IGF-I receptor signaling. Endocrinology. 2000;141:4171–9.PubMedCrossRef

30.

Galanis MFS, Bond J, Nathanielsz A, Kortt AA, Hudson PJ, Baxter RC. Ligand-binding characteristics of recombinant amino- and carboxyl-terminal fragments of human insulin-like growth factor-binding protein-3. J Endocrinol. 2001;169:123–33.PubMedCrossRef

31.

Lee KW, Liu B, Ma L, Li H, Bang P, Koeffler HP, Cohen P. Cellular internalization of insulin-like growth factor binding protein-3: distinct endocytic pathways facilitate re-uptake and nuclear localization. J Biol Chem. 2004;279:469–76.PubMedCrossRef

32.

Paharkova-Vatchkova V, Lee KW. Nuclear export and mitochondrial and endoplasmic reticulum localization of IGF-binding protein 3 regulate its apoptotic properties. Endocr Relat Cancer. 2010;17:293–302.PubMedPubMedCentralCrossRef

33.

Huq A, Singh B, Meeker T, Mascarenhas D. The metal-binding domain of IGFBP-3 selectively delivers therapeutic molecules into cancer cells. Anticancer Drugs. 2009;20:21–31.PubMedCrossRef

34.

Lee HJLJ, Hwang SJ, Lee HY. Insulin-like growth factor binding protein-3 inhibits cell adhesion via suppression of integrin β4 expression. Oncotarget. 2015;6:15150–63.PubMedPubMedCentralCrossRef

35.

Torng PL, Lee YC, Huang CY, Ye JH, Lin YS, Chu YW, Huang SC, Cohen P, Wu CW, Lin CT. Insulin-like growth factor binding protein-3 (IGFBP-3) acts as an invasion-metastasis suppressor in ovarian endometrioid carcinoma. Oncogene. 2008;27:2137–47.PubMedCrossRef

36.

Massoner P, Colleselli D, Matscheski A, Pircher H, Geley S, Jansen Durr P, Klocker H. Novel mechanism of IGF-binding protein-3 action on prostate cancer cells: inhibition of proliferation, adhesion, and motility. Endocr Relat Cancer. 2009;16:795–808.PubMedCrossRef

37.

Kim JH, Choi DS, Lee OH, Oh SH, Lippman SM, Lee HY. Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent suppression of Erk1/2 activation and Egr-1-mediated transcriptional events. Blood. 2011;118:2622–31.PubMedPubMedCentralCrossRef

38.

Du YLQ, Shi Y, Liu X, Li X, Zeng J, Gong Y, Li L, Wang X, He D. Insulin-like growth factor binding protein-3 mediates interleukin-24-induced apoptosis through inhibition of the mTOR pathway in prostate cancer. Oncol Rep. 2015;34:2273–81.PubMedPubMedCentralCrossRef

39.

Takaoka MKS, Okawa T, Michaylira CZ, Stairs DB, Johnstone CN, Andl CD, Rhoades B, Lee JJ, Klein-Szanto AJ, El-Deiry WS, Nakagawa H. IGFBP-3 regulates esophageal tumor growth through IGF-dependent and independent mechanisms. Cancer Biol Ther. 2007;6:534–40.PubMedCrossRef

40.

Chao CC, Lee WF, Yang WH, Lin CY, Han CK, Huang YL, Fong YC, Wu MH, Lee IT, Tsai YH, Tang CH, Liu JF. IGFBP-3 stimulates human osteosarcoma cell migration by upregulating VCAM-1 expression. Life Sci. 2021;265: 118758.PubMedCrossRef

41.

Lu L, Katsaros D, Wiley A, Rigault de la Longrais IA, Risch HA, Puopolo M, Yu H. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer. Clin Cancer Res. 2006;12:1208–14.PubMedCrossRef

42.

Wang JLX, Tang YL, Xu JX, Zeng ZG. The prognostic values of insulin-like growth factor binding protein in breast cancer. Medicine. 2019;98: e15561.PubMedPubMedCentralCrossRef

43.

Ng EFYKA, Nojima H, Miura M. Roles of IGFBP-3 in cell migration and growth in an endophytic tongue squamous cell carcinoma cell line. Sci Rep. 2022;12:11503.PubMedPubMedCentralCrossRef

44.

Chen CH, Chen PY, Lin YY, Feng LY, Chen SH, Chen CY, Huang YC, Huang CY, Jung SM, Chen LY, Wei KC. Suppression of tumor growth via IGFBP3 depletion as a potential treatment in glioma. J Neurosurg. 2019;132:168–79.PubMedCrossRef

45.

Yang X, Chen D, Hu J, Zhao Q, Fu X, Lv W. miR-133a-5p inhibits glioma cell proliferation by regulating IGFBP3. J Oncol. 2022;2022:8697676.PubMedPubMedCentralCrossRef

46.

Granata RTL, Lupia E, Sala G, Settanni F, Camussi G, Ghidoni R, Ghigo E. Insulin-like growth factor binding protein-3 inducesangiogenesis through IGF-I- and SphK1-dependent mechanisms. J Thromb Haemost. 2007;5:835–45.PubMedCrossRef

47.

Chang KHC-LT, McFarland EL, Afzal A, Pan H, Baxter LC, Shaw LC, Caballero S, Sengupta N, Li Calzi S, Sullivan SM, Grant MB. IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development. Proc Natl Acad Sci USA. 2007;104:10595–600.PubMedPubMedCentralCrossRef

48.

Wang YA, Sun Y, Palmer J, Solomides C, Huang LC, Shyr Y, Dicker AP, Lu B. IGFBP3 modulates lung tumorigenesis and cell growth through IGF1 signaling. Mol Cancer Res. 2017;15:896–904.PubMedCrossRef

49.

Liu BLK, Anzo M, Zhang B, Zi X, Tao Y, Shiry L, Pollak M, Lin S, Cohen P. Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene. 2007;26:1811–9.PubMedCrossRef

50.

Oh SH, Kim WY, Lee OH, Kang JH, Woo JK, Kim JH, Glisson B, Lee HY. Insulin-like growth factor binding protein-3 suppresses vascular endothelial growth factor expression and tumor angiogenesis in head and neck squamous cell carcinoma. Cancer Sci. 2012;103:1259–66.PubMedPubMedCentralCrossRef

51.

Shih HJCC, Torng PL. IGFBP3 inhibits angiogenesis through intracellular regulation of THBS1 expression. Am J Cancer Res. 2020;10:1728–44.PubMedPubMedCentral

52.

Scully TSC, Firth SM, Sedger LM, Pintar JE, Twigg SM, Baxter RC. Enhancement of mammary tumour growth by IGFBP-3 involves impaired T cell accumulation. Endocr Relat Cancer. 2018;25:111–22.PubMedCrossRef

53.

Natsuizaka MKH, Kagawa S, Whelan KA, Naganuma S, Subramanian H, Chang S, Nakagawa KJ, Rustgi NL, Kita Y, Natsugoe S, Basu D, Gimotty PA, Klein-Szanto AJ, Diehl JA, Nakagawa H. IGFBP3 promotes esophageal cancer growth by suppressing oxidative stress in hypoxic tumor microenvironment. Am J Cancer Res. 2014;4:29–41.PubMedPubMedCentral

54.

Zhao YXC, Deng Y, Ye C, Peng H. HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies. Genes Dis. 2023;11:234–51.PubMedPubMedCentralCrossRef

55.

Feng CC, Lin CC, Lai YP, Chen TS, Marthandam Asokan S, Lin JY, Lin KH, Viswanadha VP, Kuo WW, Huang CY. Hypoxia suppresses myocardial survival pathway through HIF-1alpha-IGFBP-3-dependent signaling and enhances cardiomyocyte autophagic and apoptotic effects mainly via FoxO3a-induced BNIP3 expression. Growth Factors. 2016;34:73–86.PubMedCrossRef

56.

Chen J, Lai L, Liu S, Zhou C, Wu C, Huang M, Lin Q. Targeting HIF-1alpha and VEGF by lentivirus-mediated RNA interference reduces liver tumor cells migration and invasion under hypoxic conditions. Neoplasma. 2016;63:934–40.PubMedCrossRef

57.

Vitale IMG, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019;30:36–50.PubMedCrossRef

58.

Boutilier AJES. Macrophage polarization states in the tumor microenvironment. Int J Mol Sci. 2021;22:6995.PubMedPubMedCentralCrossRef

59.

Malfitano AMPS, Napolitano F, Di Somma S, Martinelli R, Portella G. Tumor-associated macrophage status in cancer treatment. Cancers. 2020;12:1987.PubMedPubMedCentralCrossRef

60.

Sun L, Zhang X, Song Q, Liu L, Forbes E, Tian W, Zhang Z, Kang Y, Wang H, Fleming JB, Pasche BC, Zhang W. IGFBP2 promotes tumor progression by inducing alternative polarization of macrophages in pancreatic ductal adenocarcinoma through the STAT3 pathway. Cancer Lett. 2021;500:132–46.PubMedCrossRef

61.

Scully TSC, Firth SM, Sedger LM, Pintar JE, Twigg SM, Baxter RC. Enhancement of mammary tumour growth by IGFBP-3 involves impaired T cell accumulation. Endocr Relat Cancer. 2017;25:111–22.PubMedCrossRef

62.

Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, Lam EYN, Henderson MA, Bell CC, Stolzenburg S, Gilan O, Bloor S, Noori T, Morgens DW, Bassik MC, Neeson PJ, Behren A, Darcy PK, Dawson SJ, Voskoboinik I, Trapani JA, Cebon J, Lehner PJ, Dawson MA. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549:101–5.PubMedPubMedCentralCrossRef

63.

Li T, Zhang C, Zhao G, Zhang X, Hao M, Hassan S, Zhang M, Zheng H, Yang D, Liu L, Mehraein-Ghomi F, Bai X, Chen K, Zhang W, Yang J. IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma. Cancer Lett. 2020;477:19–30.PubMedPubMedCentralCrossRef

64.

Karlsson S, Nystrom H. The extracellular matrix in colorectal cancer and its metastatic settling—alterations and biological implications. Crit Rev Oncol Hematol. 2022;175: 103712.PubMedCrossRef

65.

Nguyen XX, Renaud L, Feghali-Bostwick C. Identification of impacted pathways and transcriptomic markers as potential mediators of pulmonary fibrosis in transgenic mice expressing human IGFBP5. Int J Mol Sci. 2021;22:12609.PubMedPubMedCentralCrossRef

66.

Kashyap AS, Shooter GK, Shokoohmand A, McGovern J, Sivaramakrishnan M, Croll TI, Cane G, Leavesley DI, Soderberg O, Upton Z, Hollier BG. Antagonists of IGF: vitronectin interactions inhibit IGF-I-induced breast cancer cell functions. Mol Cancer Ther. 2016;15:1602–13.PubMedCrossRef

67.

Ranke MB. Insulin-like growth factor binding-protein-3 (IGFBP–3). Best Pract Res Clin Endocrinol Metab. 2015;29:701–11.PubMedCrossRef

68.

Cai Q, Dozmorov M, Oh Y. IGFBP-3/IGFBP-3 receptor system as an anti-tumor and anti-metastatic signaling in cancer. Cells. 2020;9:1261.PubMedPubMedCentralCrossRef

69.

Kang D, Waldvogel HJ, Wang A, Fan D, Faull RLM, Curtis MA, Shorten PR, Guan J. The autocrine regulation of insulin-like growth factor-1 in human brain of Alzheimer’s disease. Psychoneuroendocrinology. 2021;127: 105191.PubMedCrossRef

70.

Silha JV, Gui Y, Mishra S, Leckstrom A, Cohen P, Murphy LJ. Overexpression of gly56/gly80/gly81-mutant insulin-like growth factor-binding protein-3 in transgenic mice. Endocrinology. 2005;146:1523–31.PubMedCrossRef

71.

Yen YCHJ, Jiang SS, Chang JS, Wang SH, Shen YY, Chen CH, Chang IS, Chang JY, Chen YW. Insulin-like growth factor-independent insulin-like growth factor binding protein 3 promotes cell migration and lymph node metastasis of oral squamous cell carcinoma cells by requirement of integrin β1. Oncotarget. 2015;7:33483.CrossRef

72.

Li Z, Habuchi T, Tsuchiya N, Mitsumori K, Wang L, Ohyama C, Sato K, Kamoto T, Ogawa O, Kato T. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10. Carcinogenesis. 2004;25:237–40.PubMedCrossRef

73.

Sampson N, Zenzmaier C, Heitz M, Hermann M, Plas E, Schafer G, Klocker H, Berger P. Stromal insulin-like growth factor binding protein 3 (IGFBP3) is elevated in the diseased human prostate and promotes ex vivo fibroblast-to-myofibroblast differentiation. Endocrinology. 2013;154:2586–99.PubMedCrossRef

74.

Butt AJ, Martin JL, Dickson KA, McDougall F, Firth SM, Baxter RC. Insulin-like growth factor binding protein-3 expression is associated with growth stimulation of T47D human breast cancer cells: the role of altered epidermal growth factor signaling. J Clin Endocrinol Metab. 2004;89:1950–6.PubMedCrossRef

75.

Le HT, Lee HJ, Cho J, Min HY, Lee JS, Lee SJ, Lee HY. Insulin-like growth factor binding protein-3 exerts its anti-metastatic effect in aerodigestive tract cancers by disrupting the protein stability of vimentin. Cancers (Basel). 2021;13:1041.PubMedCrossRef

76.

Singh B, Charkowicz D, Mascarenhas D. Insulin-like growth factor-independent effects mediated by a C-terminal metal-binding domain of insulin-like growth factor binding protein-3. J Biol Chem. 2004;279:477–87.PubMedCrossRef

77.

Schedlich LJ, Yenson VM, Baxter RC. TGF-beta-induced expression of IGFBP-3 regulates IGF1R signaling in human osteosarcoma cells. Mol Cell Endocrinol. 2013;377:56–64.PubMedCrossRef

78.

Lee YC, Jogie-Brahim S, Lee DY, Han J, Harada A, Murphy LJ, Oh Y. Insulin-like growth factor-binding protein-3 (IGFBP-3) blocks the effects of asthma by negatively regulating NF-kappaB signaling through IGFBP-3R-mediated activation of caspases. J Biol Chem. 2011;286:17898–909.PubMedPubMedCentralCrossRef

79.

Mofid MR, Gheysarzadeh A, Bakhtiyari S. Insulin-like growth factor binding protein 3 chemosensitizes pancreatic ductal adenocarcinoma through its death receptor. Pancreatology. 2020;20:1442–50.PubMedCrossRef

80.

Takaoka MHH, Andl CD, Oyama K, Naomoto Y, Dempsey KL, Klein-Szanto AJ, El-Deiry WS, Grimberg A, Nakagawa H. Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Res. 2004;64:7711–23.PubMedPubMedCentralCrossRef

81.

Martin JL, de Silva HC, Lin MZ, Scott CD, Baxter RC. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade. Mol Cancer Ther. 2014;13:316–28.PubMedCrossRef

82.

83.

Baxter RC. Nuclear actions of insulin-like growth factor binding protein-3. Gene. 2015;569:7–13.PubMedPubMedCentralCrossRef

84.

Kuenzli STC, Saurat JH. Retinoid receptors in inflammatory responses: a potential target for pharmacology. Curr Drug Targets Inflamm Allergy. 2004;3:355–60.PubMedCrossRef

85.

Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM, Cohen P. Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis. J Biol Chem. 2000;275:33607–13.PubMedCrossRef

86.

Schedlich LJ, O’Han MK, Leong GM, Baxter RC. Insulin-like growth factor binding protein-3 prevents retinoid receptor heterodimerization: implications for retinoic acid-sensitivity in human breast cancer cells. Biochem Biophys Res Commun. 2004;314:83–8.PubMedCrossRef

87.

Ikezoe T, Tanosaki S, Krug U, Liu B, Cohen P, Taguchi H, Koeffler HP. Insulin-like growth factor binding protein-3 antagonizes the effects of retinoids in myeloid leukemia cells. Blood. 2004;104:237–42.PubMedCrossRef

88.

Nielsen R, Pedersen TA, Hagenbeek D, Moulos P, Siersbaek R, Megens E, Denissov S, Borgesen M, Francoijs KJ, Mandrup S, Stunnenberg HG. Genome-wide profiling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. Genes Dev. 2008;22:2953–67.PubMedPubMedCentralCrossRef

89.

Pon CK, Firth SM, Baxter RC. Involvement of insulin-like growth factor binding protein-3 in peroxisome proliferator-activated receptor gamma-mediated inhibition of breast cancer cell growth. Mol Cell Endocrinol. 2015;399:354–61.PubMedCrossRef

90.

Lee KW, Ma L, Yan X, Liu B, Zhang XK, Cohen P. Rapid apoptosis induction by IGFBP-3 involves an insulin-like growth factor-independent nucleomitochondrial translocation of RXRalpha/Nur77. J Biol Chem. 2005;280:16942–8.PubMedCrossRef

91.

Lee KW, Cobb LJ, Paharkova-Vatchkova V, Liu B, Milbrandt J, Cohen P. Contribution of the orphan nuclear receptor Nur77 to the apoptotic action of IGFBP-3. Carcinogenesis. 2007;28:1653–8.PubMedCrossRef

92.

Yin HZS, Sun Y, Li S, Ning Y, Dong Y, Shang Y, Bai C. MicroRNA-34/449 targets IGFBP-3 and attenuates airway remodeling by suppressing Nur77-mediated autophagy. Cell Death Dis. 2017;8:e2998.PubMedPubMedCentralCrossRef

93.

Wei ZLH. IGFBP-3 may trigger osteoarthritis by inducing apoptosis of chondrocytes through Nur77 translocation. Int J Clin Exp Pathol. 2015;8:15599–610.PubMedPubMedCentral

94.

Mohanraj L, Kim HS, Li W, Cai Q, Kim KE, Shin HJ, Lee YJ, Lee WJ, Kim JH, Oh Y. IGFBP-3 inhibits cytokine-induced insulin resistance and early manifestations of atherosclerosis. PLoS ONE. 2013;8: e55084.PubMedPubMedCentralCrossRef

95.

Bai R, Cui Z, Ma Y, Wu Y, Wang N, Huang L, Yao Q, Sun J. The NF-kappaB-modulated miR-19a-3p enhances malignancy of human ovarian cancer cells through inhibition of IGFBP-3 expression. Mol Carcinog. 2019;58:2254–65.PubMedCrossRef

96.

Kim MS, Lee DY. Insulin-like growth factor binding protein-3 enhances etoposide-induced cell growth inhibition by suppressing the NF-kappaB activity in gastric cancer cells. Mol Cell Biochem. 2015;403:107–13.PubMedCrossRef

97.

Fanayan S, Firth SM, Baxter RC. Signaling through the Smad pathway by insulin-like growth factor-binding protein-3 in breast cancer cells. Relationship to transforming growth factor-beta 1 signaling. J Biol Chem. 2002;277:7255–61.PubMedCrossRef

98.

Natsuizaka M, Ohashi S, Wong GS, Ahmadi A, Kalman RA, Budo D, Klein-Szanto AJ, Herlyn M, Diehl JA, Nakagawa H. Insulin-like growth factor-binding protein-3 promotes transforming growth factor-beta1-mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal cells. Carcinogenesis. 2010;31:1344–53.PubMedPubMedCentralCrossRef

99.

100.

Kim MS, Kim SY, Arunachalam S, Hwang PH, Yi HK, Nam SY, Lee DY. c-myb stimulates cell growth by regulation of insulin-like growth factor (IGF) and IGF-binding protein-3 in K562 leukemia cells. Biochem Biophys Res Commun. 2009;385:38–43.PubMedCrossRef

101.

Tu W, Yang B, Leng X, Pei X, Xu J, Liu M, Dong Q, Tao D, Lu Y, Liu Y, Yang Y. Testis-specific protein, Y-linked 1 activates PI3K/AKT and RAS signaling pathways through suppressing IGFBP3 expression during tumor progression. Cancer Sci. 2019;110:1573–86.PubMedPubMedCentralCrossRef

102.

Wang WLMM, Kim C, Ma M, Pan ZT, Kaufmann C, Frank DA. The complementary roles of STAT3 and STAT1 in cancer biology: insights into tumor pathogenesis and therapeutic strategies. Front Immunol. 2023;14:1265818.PubMedPubMedCentralCrossRef

103.

Thota B, Arimappamagan A, Kandavel T, Shastry AH, Pandey P, Chandramouli BA, Hegde AS, Kondaiah P, Santosh V. STAT-1 expression is regulated by IGFBP-3 in malignant glioma cells and is a strong predictor of poor survival in patients with glioblastoma. J Neurosurg. 2014;121:374–83.PubMedCrossRef

104.

Spagnoli ATM, Nagalla SR, Horton WA, Pattee P, Hwa V, Chiarelli F, Roberts Jr CT, Rosenfeld RG. Identification of STAT-1 as a molecular target of IGFBP-3 in the process of chondrogenesis. J Biol Chem. 2002;277:18860–7.PubMedCrossRef

105.

Kuhn H, Frille A, Petersen MA, Oberhuber-Kurth J, Hofmann L, Glaser A, Taubenheim S, Klagges S, Kraemer S, Broschewitz J, von Laffert M, Wirtz H. IGFBP3 inhibits tumor growth and invasion of lung cancer cells and is associated with improved survival in lung cancer patients. Transl Oncol. 2023;27: 101566.PubMedCrossRef

106.

Hou YL, Luo P, Gy Ji, Chen H. Clinical significance of serum IGFBP-3 in colorectal cancer. J Clin Lab Anal. 2019;45:479–84

107.

Luo Y, Hong C-Q, Huang B-L, Ding T-Y, Chu L-Y, Zhang B, Qu Q-Q, Li X-H, Liu C-T, Peng Y-H, Guo H-P, Xu Y-W. Serum insulin-like growth factor binding protein-3 as a potential biomarker for diagnosis and prognosis of oesophageal squamous cell carcinoma. Ann Med. 2022;54:2153–66.PubMedPubMedCentralCrossRef

108.

Lombardo M, Cui P, Chen Y, Waili N, Li Y, Ma C, Li Y. Associations of serum C-peptide and insulin-like growth factor binding proteins-3 with breast cancer deaths. PLoS ONE. 2020;15:e0242310.CrossRef

109.

Bao L, Liu H, You B, Gu M, Shi S, Shan Y, Li L, Chen J, You Y. Overexpression of IGFBP3 is associated with poor prognosis and tumor metastasis in nasopharyngeal carcinoma. Tumor Biol. 2016;37:15043–52.CrossRef

Titel: The role of IGFBP-3 in tumor development and progression: enlightenment for diagnosis and treatment
verfasst von: Yudi Wang
He Zhang
Xuehua Zhang
Peizheng Mu
Leilei Zhao
Ruomei Qi
Yurui Zhang
Xiao Zhu
Yucui Dong
Publikationsdatum: 01.06.2024
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 6/2024
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-024-02373-x

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The role of IGFBP-3 in tumor development and progression: enlightenment for diagnosis and treatment

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2024

Therapeutic targeting of TNIK in papillary thyroid carcinoma: a novel approach for tumor growth suppression

Combination of an aurora kinase inhibitor and the ABL tyrosine kinase inhibitor asciminib against ABL inhibitor-resistant CML cells

PAQR4 oncogene: a novel target for cancer therapy

WDR1 promotes prostate cancer progression through Wnt/β-catenin signaling

In silico and network pharmacology analysis of fucosterol: a potent anticancer bioactive compound against HCC

Evaluation of the cytotoxic activities of the essential oil from Pistacia atlantica Desf. oleoresin on human gastric cancer cell lines

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie